When starting treatment in the third trimester, women taking dolutegravir more likely to achieve undetectable viral loads at the time of giving birth compared with those taking efavirenz.
A pilot scheme that immediately rebooks and provides a reminder for an HIV retest six months later increases attendance by 25%.
People on integrase inhibitors found to gain more weight on average than those on other treatment regimens
Modelling finds PrEP has the potential to avert between 3% and 8% of HIV infections in 13 African and Caribbean countries by 2030 if three key populations can access it.
Despite the country’s successful treatment programme, modelling suggests the rate of new infections is likely to rise – unless prevention is strengthened and groups such as migrants included.
Malawi trial finds half of those offered the opportunity to self-test for HIV during an outpatient visit accepted it, compared to less than 15% of those offered provider-initiated testing.
Viral load testing trial finds 49% are virally unsuppressed while one in five are failing their treatment with suspected drug resistance.
Study with transgender women suggests taking on-demand PrEP with hormone therapy may result in drug levels too low for HIV prevention.
South African study finds co-trimoxazole did not increase protection against pneumonia or diarrhoea among HIV-exposed infants in their first year of life. But in Malaria-ridden areas, there is still a case.
46% of men who have sex with men in West Africa trade sex for material goods – with younger men and those who experience stigma more likely to do so.
A network of micro-pharmacists trained to provide sexual reproductive health services in Uganda doubled contraceptive use - but has little impact on HIV knowledge.
Study identifies new structural drivers of Uganda’s HIV epidemic alongside the persistence of known drivers such as stigma and gender-based violence.
New policy brief recommends screening for HIV and syphilis using a single test to reduce mother-to-child transmission of syphilis, which is linked to 200,000 stillbirths annually.
Global analysis of death rates among women living with HIV during the first four years of antiretroviral treatment (ART) finds most deaths occur within three months – with some distinct regional variations.
Ambitious HIV and sexual health initiative, DREAMS, is successfully reaching young adolescent girls in Kenya and South Africa one year after implementation.
A review of HIV incidence among young people in east and southern Africa since antiretroviral treatment (ART) roll-out reveals failures to reach the highest-risk young women.
